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Abstract
Introduction: Pre-emptive isolation of suspected methicillin-resistant Staphylococcus aureus (MRSA) carriers is a
cornerstone of successful MRSA control policies. Implementation of such strategies is hampered when using
conventional cultures with diagnostic delays of three to five days, as many non-carriers remain unnecessarily
isolated. Rapid diagnostic testing (RDT) reduces the amount of unnecessary isolation days, but costs and benefits
have not been accurately determined in intensive care units (ICUs).
Methods: Embedded in a multi-center hospital-wide study in 12 Dutch hospitals we quantified cost per isolation
day avoided using RDT for MRSA, added to conventional cultures, in ICUs. BD GeneOhm™ MRSA PCR (IDI) and
Xpert MRSA (GeneXpert) were subsequently used during 17 and 14 months, and their test characteristics were
calculated with conventional culture results as reference. We calculated the number of pre-emptive isolation days
avoided and incremental costs of adding RDT.
Results: A total of 163 patients at risk for MRSA carriage were screened and MRSA prevalence was 3.1% (n = 5).
Duration of isolation was 27.6 and 21.4 hours with IDI and GeneXpert, respectively, and would have been 96.0
hours when based on conventional cultures. The negative predictive value was 100% for both tests. Numbers of
isolation days were reduced by 44.3% with PCR-based screening at the additional costs of €327.84 (IDI) and
€252.14 (GeneXpert) per patient screened. Costs per isolation day avoided were €136.04 (IDI) and €121.76
(GeneXpert).
Conclusions: In a low endemic setting for MRSA, RDT safely reduced the number of unnecessary isolation days on
ICUs by 44%, at the costs of €121.76 to €136.04 per isolation day avoided.
Introduction
Nosocomial infections caused by methicillin-resistant
Staphylococcus aureus (MRSA) have been associated
with increased mortality and high health care costs
[1,2]. There is considerable geographic variation in the
prevalence of nosocomial MRSA infections. In intensive
care units (ICUs) in the US the prevalence of MRSA
among clinical S. aureus isolates is over 55% [3,4], while
in countries with a national search and destroy policy
for MRSA, such as Scandinavian countries and the
Netherlands, the prevalence among bacteremia isolates
is still around 1% [5]. Pre-emptive isolation of patients
considered at high risk for MRSA carriage is considered
a cornerstone of such a control policy and has been
shown to reduce ICU acquired MRSA infections in
medical ICUs [6]. However, the vast majority of patients
considered at increased risk for carriage will not be
colonized with MRSA, yielding considerable amounts of
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unnecessary isolation days as conventional microbiologi-
cal culture methods have a diagnostic delay of three to
five days. Isolation measures are costly [7,8] and may
compromise the quality of patient care [9].
Rapid molecular screening for MRSA carriage may
reduce the logistical and financial burdens associated
with pre-emptive isolation of ICU patients. However,
the costs and effects of such diagnostic tests have not
been determined for use in ICUs [10]. Therefore, we
quantified costs and benefits of two rapid screening
tests for MRSA on ICUs in a multi-center study in the
Netherlands.
Materials and methods
Study design and setting
A prospective multi-center study was performed in 12
Dutch hospitals (5 university hospitals, 7 teaching hospi-
tals) between December 2005 and June 2008. The effects
of rapid diagnostic testing (RDT) of MRSA, using PCR
added to screening with conventional microbiological
culture methods for patients eligible for MRSA screen-
ing, were evaluated. Two real time PCR assays were sub-
sequently evaluated: BD GeneOhm™ MRSA PCR
(previously known as IDI-MRSA) (’IDI’, BD Diagnostics,
San Diego, CA USA) between December 2005 and May
2007, and Xpert MRSA assay (’GeneXpert’, Cepheid,
Sunnyvale, CA USA) between April 2007 and June 2008.
PCR-based testing was compared to concurrently per-
formed conventional microbiological techniques. We
will refer to the study period using BD GeneOhm™
MRSA PCR as the ‘IDI study’ and to the study period
using Xpert MRSA assay as the ‘GeneXpert study’.
Eligibility for screening was based on the risk profile
for MRSA carriage, as defined in Dutch guidelines
(Table 1). Proven MRSA carriers were not included.
Before onset of the study, patients categorized as at high
risk for MRSA carriage were screened and pre-emptively
isolated until conventional microbiological culture
results had demonstrated absence of MRSA. During
isolation, patients were nursed in a single-patient room
(preferably with anteroom) and with barrier precautions.
This practice has been used for more than 20 years and
is routine in all Dutch hospitals. The current interven-
tion implied that continuation (or discontinuation) of
pre-emptive isolation was decided immediately upon the
results of PCR testing, which was performed as soon as
possible in patients meeting the screening criteria. The
IDI and GeneXpert study included patients in both the
ICU and nursing departments. However, because of lack
of experience with RDT for MRSA carriage, the results
of RDT were initially not used to discontinue isolation
measures in ICU patients. Yet, from October 2006 on,
isolation measures were also discontinued upon RDT
results in ICUs. Results of the study in nursing depart-
ments have been published elsewhere [10].
The institutional review board was informed although
approval for the study and informed consent were not
required as the intervention, screening for MRSA, con-
cerns usual care, provides direct benefit to patients and
is part of the regular infection control program con-
ducted by the department of hospital hygiene and infec-
tion control.
Cost analysis
The primary endpoint was the cost per isolation day
avoided with rapid MRSA screening tests when added
to conventional screening. Computerized reporting of all
steps in the microbiology laboratory and recording the
time point of start and discontinuation of isolation by
the infection control practitioners allowed exact deter-
mination of turn around times (TATs). Isolation days
avoided are the number of additional isolation days
should PCR not have been performed, and isolation
would only have been discontinued on negative conven-
tional cultures results. It was determined using the time
of availability of conventional culture results. If the PCR
result was positive, isolation measures were continued
awaiting conventional cultures, and when cultures
Table 1 Patients considered at high risk for MRSA colonization and eligible for screening and pre-emptive isolation
according to the guideline of the Dutch Working Party on Infection Preventiona
Patients transferred from a foreign hospital who 1) have been admitted there for more than 24 hours, or
2) have undergone surgery, or
3) had a catheter, or
4) were intubated, or
5) have wounds or infections such as abscesses or furunculosis
Patients transferred from a Dutch hospital or nursing home with an uncontrolled MRSA outbreak
Patients who are contacts of an unexpected MRSA carrier
Patients treated for MRSA carriage when control cultures are not performed yet or unknown
Children who had been adopted from foreign countries
Patients who have professional exposure to living pigs on pig farms or patients living on a pig farmb
aMRSA guideline: http://www.wip.nl/free_content/richtlijnen/mrsa%20ziekenhuis080310.pdf. bDuring the study (July 2006) added as a risk factor. MRSA,
methicillin-resistant Staphylococcus aureus.
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appeared negative, isolation measures were discontinued
with no isolation days saved. Isolation days avoided by
patients in the IDI study for whom PCR testing was not
used to change isolation measures, were calculated upon
the hypothetical scenario that these results had been
used in decision making on termination of isolation.
When the exact moment of the start or discontinuation
of isolation was missing the median of the duration of
isolation using the IDI, GeneXpert or conventional cul-
ture was imputed. We determined incremental costs of
adding rapid screening tests to the current Dutch
MRSA policy. Incremental costs of rapid screening tests
were calculated and included costs attributed to rapid
screening and costs because of false negative test results.
The incremental costs were divided by the number of
avoided isolation days to calculate the cost per isolation
day avoided. Costs were calculated from the hospital
perspective. A detailed description of the cost analyses
has been published elsewhere [10].
Microbiological analyses
Samples
After meeting the eligibility criteria, swabs from the
anterior nares, throat, perineum and, if present, wounds,
catheter insertion sites, sputum and urine samples (in
case of an indwelling urinary catheter) were obtained as
soon as possible. Swabs in liquid Stuart transport media
(Becton Dickinson) were used for MRSA PCR and these
samples were taken firstas it was important to avoid, as
much as possible, a false negative PCR. Subsequently
swabs (according to local protocol, mainly cotton swabs)
were taken for conventional culture. Specimens were
transported at room temperature and refrigerated until
being processed.
Conventional microbiological MRSA screening
Specimens for conventional microbiological cultures
were processed according to the guidelines of the Dutch
Society of Medical Microbiology [11], which includes a
broth enrichment step for all swabs, combined with
selective and non-selective agar plates.
MRSA PCR
During the IDI study specimens were processed with the
BD GeneOhm™ MRSA PCR assay run on the SmartCy-
cler platform (Cepheid, Sunnyvale, CA USA). Specimen
preparation adaptations were made for swabs from
wounds (50 μl cell suspension added to lysis tube, lysis
tube not centrifuged) and urine and pus (first centri-
fuged for 10 minutes and subsequently sample buffer
was added to the pellet). The PCR assay was performed
according to manufacturers’ manual, with an additional
freeze-thaw cycle of the prepared lysates to reduce inhi-
bitory effects of interfering substances. The laboratory
could decide on the procedure as long as optical control
was performed to confirm freezing. In the GeneXpert
study the Xpert MRSA assay run on a 4-site GeneX-
pert® system (Cepheid, Sunnyvale, CA USA) was used
in accordance with manufacturers’ protocol. Nose,
throat and perineum specimen were processed sepa-
rately, and additional specimens, when present, were
pooled in the fourth cartridge.
On a patient level, PCR-based screening results were
considered positive if at least one PCR result was posi-
tive and were considered negative if the nasal swab and
at least one other test result were negative (and the
other sites negative or non-conclusive). In case of a
non-conclusive PCR result of the nasal swab, the overall
test result for that patient was considered non-conclu-
sive and isolation was continued until conventional cul-
tures were negative or until a second PCR test
performed on a new nasal swab was negative. Results,
both positive and negative, were immediately reported
to the wards. MRSA PCR was performed within 24
hours on working days, and not in weekends and on
holidays (except for five hospitals during the GeneXpert
study). Final results of conventional cultures were con-
sidered as the gold standard. Therefore, isolation mea-
sures based upon a positive PCR result were withdrawn
when conventional culture results were negative.
Statistical analysis
Test characteristics were determined at the patient level
based on a combination of the results from all anatomi-
cal sites sampled. For determination of test characteris-
tics patients were either MRSA negative (including
those with non-conclusive results) or positive.
Continuous variables were compared using the Mann-
Whitney U test; categorical variables were compared
with the c2 test and Fisher exact test. All analyses were
performed using SPSS.
Results
Patient population and test characteristics
A total of 163 patients were included yielding 941
screening samples (163 nares, 163 throat, 163 perineum,
129 wound, 85 urine, 52 sputum, 186 catheter insertion
sites, drains and other samples): 5.8 sites were tested per
patient. Eighty-nine patients were screened with BD
GeneOhm™ MRSA PCR (Figure 1) and 74 with Xpert
MRSA assay (Figure 2). In total 787 MRSA PCRs were
performed, 519 (5.8 per patient, all specimens processed
separately) and 268 (3.6 per patient, including pooled
specimens) in the IDI and GeneXpert studies, respec-
tively. Numbers of patients included per hospital ranged
from 1 to 57. Contact with an MRSA carrier was the
most important reason for screening (Table 2). The pre-
valence of MRSA carriage, based upon conventional
microbiological cultures, was 3.1% (n = 5 patients), with
the highest carriage rate among those screened because
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of contact with pigs. Using the results of conventional
cultures as reference, sensitivity, specificity, and posi-
tive (PPV) and negative predictive (NPV) values for
detecting MRSA (at the patient level) were 100% (95%
confidence interval (CI) 0.46 to 1), 94.3% (95% CI 0.89
to 0.97), 35.7% (95% CI 0.14 to 0.64) and 100% (95%
CI 0.97 to 1) for both screening tests together. For IDI
the specificity and NPV were 93.3% (95% CI 0.84 to
0.97) and 100% (95% CI 0.94- to 1), respectively. As
there were no patients with MRSA detected in the IDI
study, sensitivity and PPV could not be determined.
For GeneXpert sensitivity, specificity, PPV and NPV
were 100% (95% CI 0.46 to 1), 95.7% (95% CI 0.87 to
0.99), 62.5% (95% CI 0.26 to 0.90) and 100% (95% CI
0.93 to 1), respectively.
Effect on pre-emptive isolation
Median duration of pre-emptive isolation of ICU
patients was 27.6, 21.4 and 96.0 hours, for patients in
which isolation was discontinued upon IDI, GeneXpert
and conventional culture results, respectively (Table 3).
Pre-emptive isolation was discontinued upon a negative
PCR result in 102 (62.6%) patients while 22 patients
(13.5%) remained in isolation because of a positive (n =
14) or non-conclusive (n = 8) PCR test, 4 remained in
isolation for other reasons and 35 (21.5%) patients with
a negative PCR result remained in isolation during the
initial phase of the IDI study conform the protocol
before October 2006 (up to October 2006 results of
RDT were not used to discontinue isolation measures in
ICU patients, because of lack of experience with RDT).
Figure 1 Flowchart of patients included in the IDI study. aContact screening patients were only assessed when the contact screening was of
limited size as the number of available slots on the SmartCycler is 14 (maximum of four patients). bPCR of the nose swab was unresolved. PCR,
polymerase chain reaction.
Figure 2 Flowchart of patients included in the GeneXpert study. aPCR of the nose swab was unresolved (n = 12) or the nose swab was
negative and all other sites were non-conclusive (n = 2). PCR, polymerase chain reaction.
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Most of the patients with positive PCR results (9/14,
64.3%) appeared MRSA negative with conventional cul-
tures. There were no false negative PCR results.
In 137 (84.0%) patients isolation could have been discon-
tinued based on a negative PCR result (84.3% in IDI study
and 83.8% in GeneXpert study). The estimated total number
of isolation days needed based on the conventional culture
strategy (and incorporating real discharge (or decease) times)
was 831 days. PCR could have reduced the number of isola-
tion days by 44.3% to 463 days, avoiding 368 isolation days.
Cost per isolation day avoided
Costs per test were €56.22 and €69.62 for IDI and Gen-
eXpert, respectively (Table 4). The costs per isolation
day avoided were €136.04 (€5.67 per hour) in the IDI
study, and €121.76 (€5.07 per hour) in the GeneXpert
study. If samples in the IDI study would have been
pooled resulting in < 4.6 MRSA PCRs per patient, the
cost per isolation day avoided would have been lower
for IDI than for the GeneXpert. As there were no false
negative test results no additional costs for contact
screening and isolation measures were made.
Discussion
In ICUs with an average prevalence of MRSA carriage
among screened patients of 3.1%, the guiding of pre-
emptive isolation upon RDT appeared safe and reduced
the number of isolation days needed by 44% at the cost
of €121.76 to €136.04 per isolation day avoided. Imple-
mentation of these techniques will markedly enhance
the feasibility of control measures for nosocomial spread
of MRSA. Future technical developments will probably
reduce prices per isolation day avoided.
Little is known about costs of isolation measures in
ICUs. In a French study performed in a medical ICU
between 1993 and 1997, costs of an MRSA control pol-
icy (including contact isolation and microbiological
screening) were calculated to be $655 to $705 per
patient for an average length of stay of 20 days ($33 to
$35 per day) [2]. Taking investment costs into account
would increase costs to $1,450 per patient ($73 per day).
More recent data are not available for the ICU. In other
studies on nursing wards, estimated costs of an isolation
day ranged from €26.34 to €46.07 [8,10,12]. From these
data it is obvious that the costs per isolation day avoided
as estimated in the present study are higher than the
actual costs of isolation. Of note, these estimates do not
Table 2 Demographic and clinical characteristics of
patients
Characteristics (Number = 163)
Men, Number (%) 97 (59)
Age, median (IQR), years 53 (20.4-67.9)
Hospital discharge alive, Number (%) 134 (82)
Reason for MRSA suspicion, Number (%)
Contact with MRSA carrier 91 (56)
Treatment in foreign hospital 50 (31)
Contact with pigs 11 (7)
Other 11 (7)
MRSA carriage, Number (%)
Overall 5/163 (3)
Contact with MRSA carrier 1/91 (1)
Treatment in foreign hospital 1/50 (2)
Contact with pigs 3/11 (27)
Other 0/11 (0)
IQR, Interquartile range; MRSA, methicillin-resistant Staphylococcus aureus
Table 3 Turn-around times and duration of isolation with different screening methods; values are expressed as
medians (interquartile range)
Conventional culturea BD GeneOhm™ MRSA PCR Xpert MRSA assayb
(Number = 163) (Number = 89) (Number = 74)
Time from start of isolation to delivery of specimen to lab, hoursc 14.6 (0.5-19.9) 16.3 (0-19.9)d 5.8 (0.5-18.2)d
Time from arrival in the lab to definite test result, hourse 72.5 (67.0-96.0) 18.5 (5.3-24.0) 2.6 (1.7-20.4)
Time from start isolation to definite test result, hours 91.2 (71.0-113.8) 25.2 (18.0-43.4) 21.1 (5.3-28.3)
Isolation discontinued based on test, numberf 48/163 40/89 62/74
Time from definite test result to discontinuation of isolation, hoursg 0.7 (0-1.9) 1.0 (0.2-6.0) 0.2 (0-0.5)
Duration of isolation, hoursg 96.0 (78.7-113.5) 27.6 (23.0-48.5) 21.4 (14.6-37.2)
aTurn-around times of conventional cultures during IDI study: time from start of isolation to delivery of specimen to laboratory: 16.3 hours (0 to 19.9); time from
arrival in the laboratory to definite result: 76.1 hours (68.4 to 97.9); time from definite test result to discontinuation of isolation: 0.7 hours (0 to 1.9); time from
start of isolation to definite test result: 91.9 hours (71.8 to114.0); duration of isolation 96.0 hours (86.2 to 113.5). Turn-around times of conventional cultures
during GeneXpert study: time from start of isolation to delivery of specimen to laboratory: 5.8 hours (0.48 to 18.2); time from arrival in the laboratory to definite
result: 69.4 hours (65.0 to 84.7); time from definite test result to discontinuation of isolation 1.0 hours (0.5 to 1.4); time from the start of isolation to definite test
result 88.1 hours (70.6 to 100.1); duration of isolation: 98.9 hours (71.3 to 129.8). bIn 14 patients (18.9%) the exact moment of start or discontinuation of isolation
was missing. cWhen not all specimens did arrive simultaneously, time of last specimen to arrive was noted. dTime for samples to arrive at the microbiology
laboratories was longer during the IDI study than during the GeneXpert study, which was caused by one hospital (n = 35) that had an above average delivery
time (median 18.0 hours) and only participated in the IDI study, and because the MRSA PCR was not performed on weekends and on holidays during the IDI
study. eIncluding weekends and public holidays when the MRSA PCR was not performed in all hospitals. fIn the other patients isolation measures were
discontinued on discharge (n = 9), when the patient died (n = 2) or because of other reasons (n = 2). gIn patients where isolation was discontinued based on a
negative test result. MRSA, methicillin-resistant Staphylococcus aureus; PCR, polymerase chain reaction
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include positive effects because of less logistical con-
straints when reducing numbers of isolation days and
the costs associated with infections prevented through
such an intervention.
Incremental costs are determined by costs for RDT
and costs for the consequences of false negative cases.
Costs for MRSA PCR are mainly influenced by the
microbiological platform used and the number of PCR
tests performed per patient. During the IDI study all
swabs were analyzed separately while in the GeneXpert
study the fourth swab and further swabs were pooled,
which reduces the costs. When swabs are pooled using
the IDI, this test will be less expensive than the GeneX-
pert. No false negative cases were observed in our study
and therefore no additional costs associated with false
negative screening results were included in the cost ana-
lysis. Yet, reported MRSA PCR sensitivity rates are
93.8% (95% CI 88.7 to 96.6) for IDI [13] and have ran-
ged from 83.9% to 90.0% for GeneXpert MRSA assay
[14-16]. In the Netherlands false negative results would
lead to contact screenings among patients and health
care workers, which would have financial consequences.
The absence of false negative findings in our study,
therefore, leaves some uncertainty in our calculation of
extra costs attributable to PCR-based screening.
As compared to the current Dutch policy, addition of
PCR-based testing for MRSA screening in ICUs could
reduce the number of isolation days by 44% at a cost of
€121.76 (GeneXpert study) or €136.04 (IDI study) per
isolation day avoided. This is less than the reported 54%
to 60% on general wards [10,17]. This lower profit for
ICU patients probably is related to limitations in diag-
nostic capacity. ICUs patients usually have catheters, IV
lines and often multiple wounds, which are all screened
for MRSA according to protocol. The platforms used
are not suited for the large volumes of multiple tests in
a short period of time, as only 16 and 4 tests could be
performed simultaneously on the Smartcycler and Gen-
eXpert, respectively. This endorses the need for large
volume testing or pooling of swabs in ICU patients to
decrease unnecessary pre-emptive isolation time.
Another option would be to use chromogenic agar-
based screening, which has a slightly longer turn around
time in the laboratory, but can be performed in large
volumes and is easily implemented in routine laboratory
practice, including weekend days. In general wards,
chromogenic screening reduced the number of isolation
days needed by 47%, which is even more than the 44%
in this study, at a cost of €6.74 per isolation day avoided
[10]. Although not tested in this study, chromogenic
agar-based screening is also likely to be a cost-saving
alternative on ICUs.
In high endemic countries, routine surveillance for
MRSA carriage in ICUs, with subsequent isolation of
documented carriers, has been associated with reduc-
tions in MRSA infections in ICUs and hospital-wide
[18-20]. General pre-emptive isolation has been shown
to reduce ICU- acquired MRSA infections in medical
ICUs [6]; however, implementation is not feasible in
most ICUs in high endemic areas due to a shortage of
isolation rooms. As PCR-based testing decreased the
number of pre-emptive isolation days by only 44%, it is
unlikely that the molecular screening tests used in our
study would enable implementation of pre-emptive iso-
lation in high endemic settings. Different MRSA screen-
ing regimes, for example by varying the number of body
sites tested, performing pooling of specimens or by
omitting conventional cultures could minimize cost [21],
and may be an appropriate alternative for high endemic
countries.
The present study has several limitations, such as the
quasi-experimental design of the PCR intervention study
and the second-best approach that was needed to esti-
mate the time to end of isolation measures of the 35
Table 4 Costs of adding rapid diagnostic testing of methicillin-resistant Staphylococcus aureus (MRSA) to the currently
used MRSA policy
Number of units Cost/unit (€) Additional cost (€)
IDI study
Total cost per testa 56.22
Total cost of test strategy in this study 519 29,178.18
PCR cost per patient tested (n = 89) 327.84
GeneXpert study
Total cost per testb 69.62
Total cost of test strategy in this study 268 18,658.16
PCR cost per patient tested (n = 74) 252.14
aCosts for BD GeneOhm™ MRSA PCR (assuming 200 patients per year are screened) include: assay and platform costs (price SmartCycler €41,650), depreciation
(5 years) and 8% maintenance costs, personnel costs (laboratory staff and medical microbiologist), and additional costs (Liquid Stuart’s swabs, gloves,
consumables). A detailed description of the cost analyses has been published elsewhere [10]. bCosts for Xpert MRSA PCR include: assay and platform costs (price
GeneXpert €63,813.75), depreciation (5 years) and 8% maintenance costs, personnel costs (laboratory staff and medical microbiologist), and additional costs
(Liquid Stuart’s swabs, gloves, consumables). A detailed description of the cost analyses has been published elsewhere [10]. PCR, polymerase chain reaction.
Wassenberg et al. Critical Care 2012, 16:R22
http://ccforum.com/content/16/1/R22
Page 6 of 8
patients in the IDI study for whom PCR testing was not
used to change isolation measures. However, exclusion
of these patients did not change results.
Conclusions
In conclusion, our study shows that PCR-based testing
safely reduced the number of pre-emptive isolation days
by 44% on ICUs in a low endemic setting for MRSA.
Cost-effectiveness of the intervention remains to be
determined. However, the benefit of PCR-based screen-
ing will increase using diagnostic procedures more suita-
ble for large volume testing.
Key messages
• MRSA prevalence was 3.1% (n = 5) in 163 patients
at risk for MRSA carriage, and therefore pre-emp-
tively isolated, in ICUs in 12 Dutch hospitals.
• Duration of pre-emptive isolation was 27.6 and
21.4 hours with IDI- and GeneXpert- based screen-
ing, respectively, and would have been 96.0 hours
when based on conventional cultures.
• The number of isolation days was reduced by
44.3% with PCR-based screening at the additional
costs of €327.84 (IDI) and €252.14 (GeneXpert) per
patient screened.
• Costs per isolation day avoided were €136.04 (IDI)
and €121.76 (GeneXpert).
• In a low endemic setting for MRSA, RDT safely
reduced the number of unnecessary isolation days
on ICUs.
Abbreviations
CI: confidence interval; ICUs: intensive care units; MRSA: methicillin-resistant
Staphylococcus aureus; NPV: negative predictive value; PCR: polymerase chain
reaction; PPV: positive predictive value; RDT: rapid diagnostic testing; TATs:
turn-around times.
Acknowledgements
This work was supported by a grant (nr 945-05-041) from ZonMw, The
Hague, The Netherlands. The investigators also received unrestricted
research grants from GeneOhm Sciences Inc. Belgium (currently Becton
Dickinson) and Cepheid Europe, France. MJMB was supported by the
Netherlands Organization for Scientiﬁc Research (VICI NWO Grant
918.76.611). The funding source did not have any role in the study design;
in the collection, analysis, and interpretation of data; in the writing of the
manuscript; or in the decision to submit the manuscript for publication.
Author details
1Department of Medical Microbiology, University Medical Center,
Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands. 2Department of
Internal Medicine and Infectious Diseases, University Medical Center,
Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands. 3Laboratory for
Microbiology and Infection Control, Amphia Hospital, Molengracht 21, Breda,
4818 CK, The Netherlands. 4Department of Medical Microbiology and
Infection Control, VU University Medical Center, De Boelelaan 1118,
Amsterdam, 1081 HZ, The Netherlands. 5Department of Medical
Microbiology, Hygiene and Infection Prevention, Slingeland Hospital,
Kruisbergseweg 25, Doetinchem, 7000 AD, The Netherlands. 6Public Health
Laboratory Tilburg, St. Elisabeth Hospital, Hilvarenbeekseweg 60, Tilburg,
5022 GC, The Netherlands. 7Department of Medical Microbiology and
Infection Prevention, Haga Hospital, Leyweg 275, The Hague, 2545 CH, The
Netherlands. 8Department of Medical Microbiology, Radboud University
Nijmegen Medical Center, Geert Grooteplein-Zuid 10, Nijmegen, 6525 GA,
The Netherlands. 9Laboratory of Medical Microbiology and Immunology,
Diakonessenhuis, Bosboomstraat 1, Utrecht, 3582 KE, The Netherlands.
10Department of Medical Microbiology, Academic Medical Center,
Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands. 11Department of
Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital,
Weg door Jonkerbos 100, Nijmegen, 6532 SZ, The Netherlands.
12Department of Medical Microbiology, CAPHRI, Maastricht University, P.
Debyelaan 25, Maastricht, 6229 HX, The Netherlands. 13Laboratory for
Pathology and Medical Microbiology, PAMM Institute, De Run 6250,
Veldhoven, 5504 DL, The Netherlands. 14Laboratory for Medical Microbiology
and Immunology, Alysis Zorggroep, Wagnerlaan 55, Arnhem, 6815 AD, The
Netherlands. 15National Institute of Public Health and the Environment,
Antonie van Leeuwenhoeklaan 9, Bilthoven, 3721 MA, The Netherlands.
16Julius Center for Health Sciences and Primary Care, University Medical
Center,Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.
Authors’ contributions
MW, JK, AB, ST, AT, CVG, CV, AV, MW and MB designed the study and wrote
the manuscript. MW, AW and MB performed the statistical analysis of data.
MW, JK, SE, RB, AB, EE, WM, ST, AT, CVG, CV, AV, PW, MW, TZ, AW and MB
participated in the collection and interpretation of data and critically revised
the manuscript for important intellectual content. All authors read and
approved the final manuscript.
Competing interests
JAJW reports receiving advisory board and or consulting fees from 3M,
Destiny Pharma, Novabay and Wyeth, and lecture fees from 3M and Becton
Dickinson. CMJEV-G reports receiving lecture fees from Pfizer and
bioMérieux. CEV reports receiving lecture fees from Pfizer and bioMérieux.
AV reports advisory board fees from Cardinal Health and JohnsonDiversey,
as well as lecture fees from 3M, Pfizer and bioMérieux. MJMB reports
receiving advisory board fees from Ipsat therapies, 3M, Cepheid and
Novartis; consulting fees from Novartis, 3M and Bayer, and lecture fees from
Cepheid, Kimberly Clark and Pfizer. All other authors declare that they have
no competing interests.
Received: 18 July 2011 Revised: 21 December 2011
Accepted: 7 February 2012 Published: 7 February 2012
References
1. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW,
Carmeli Y: Comparison of mortality associated with methicillin-resistant
and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-
analysis. Clin Infect Dis 2003, 36:53-59.
2. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C: Control of endemic
methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an
intensive care unit. JAMA 1999, 282:1745-1751.
3. NNIS system: National Nosocomial Infections Surveillance (NNIS) System
Report, data summary from January 1992 through June 2004, issued
October 2004. Am J Infect Control 2004, 32:470-485.
4. Styers D, Sheehan DJ, Hogan P, Sahm DF: Laboratory-based surveillance
of current antimicrobial resistance patterns and trends among
Staphylococcus aureus: 2005 status in the United States. Ann Clin
Microbiol Antimicrob 2006, 5:2.
5. RIVM: European Antimicrobial Resistance Surveillance System.[http://
www.rivm.nl/earss/database/].
6. Harbarth S, Masuet-Aumatell C, Schrenzel J, Francois P, Akakpo C, Renzi G,
Pugin J, Ricou B, Pittet D: Evaluation of rapid screening and pre-emptive
contact isolation for detecting and controlling methicillin-resistant
Staphylococcus aureus in critical care: an interventional cohort study.
Crit Care 2006, 10:R25.
7. Vriens M, Blok H, Fluit A, Troelstra A, van der Werken C, Verhoef J: Costs
associated with a strict policy to eradicate methicillin-resistant
Staphylococcus aureus in a Dutch University Medical Center: a 10-year
survey. Eur J Clin Microbiol Infect Dis 2002, 21:782-786.
8. van Rijen MM, Kluytmans JA: Costs and benefits of the MRSA Search and
Destroy policy in a Dutch hospital. Eur J Clin Microbiol Infect Dis 2009,
28:1245-1252.
Wassenberg et al. Critical Care 2012, 16:R22
http://ccforum.com/content/16/1/R22
Page 7 of 8
9. Stelfox HT, Bates DW, Redelmeier DA: Safety of patients isolated for
infection control. JAMA 2003, 290:1899-1905.
10. Wassenberg MW, Kluytmans JA, Box AT, Bosboom RW, Buiting AG, van
Elzakker EP, Melchers WJ, van Rijen MM, Thijsen SF, Troelstra A,
Vandenbroucke-Grauls CM, Visser CE, Voss A, Wolffs PH, Wulf MW, van
Zwet AA, de Wit GA, Bonten MJ: Rapid screening of methicillin-resistant
Staphylococcus aureus (MRSA) using PCR and chromogenic agar: a
prospective study to evaluate costs and effects. Clin Microbiol Infect 2010,
16:1754-1761.
11. van Griethuysen A, de Neeling H, Vandenbroucke-Grauls C, Vos G,
Kluytmans J: Richtlijn Detectie van methicillineresistente Staphylococcus
aureus in Nederland. Ned Tijdschr Med Microbiol 2003, 11:58-65.
12. Wernitz MH, Keck S, Swidsinski S, Schulz S, Veit SK: Cost analysis of a
hospital-wide selective screening programme for methicillin-resistant
Staphylococcus aureus (MRSA) carriers in the context of diagnosis
related groups (DRG) payment. Clin Microbiol Infect 2005, 11:466-471.
13. Luteijn JM, Hubben GA, Pechlivanoglou P, Bonten MJ, Postma MJ:
Diagnostic accuracy of culture-based and PCR-based detection tests for
methicillin-resistant Staphylococcus aureus: a meta-analysis. Clin
Microbiol Infect 2011, 17:146-154.
14. Rossney AS, Herra CM, Brennan GI, Morgan PM, O’Connell B: Evaluation of
the XpertTM MRSA Assay on the GeneXpert Real-Time PCR Platform for
Rapid Detection of MRSA from Screening Specimens. J Clin Microbiol
2008, 46:3285-3290.
15. Brenwald NP, Baker N, Oppenheim B: Feasibility study of a real-time PCR
test for meticillin-resistant Staphylococcus aureus in a point of care
setting. J Hosp Infect 2010, 74:245-249.
16. Wolk DM, Picton E, Johnson D, Davis T, Pancholi P, Ginocchio CC,
Finegold S, Welch DF, de Boer M, Fuller D, Solomon MS, Rogers B,
Mehta MS, Peterson LR: Multicenter evaluation of the Cepheid Xpert
methicillin-resistant Staphylococcus aureus (MRSA) test as a rapid
screening method for detection of MRSA in nares. J Clin Microbiol 2009,
47:758-764.
17. Uckay I, Sax H, Iten A, Camus V, Renzi G, Schrenzel J, Perrier A, Pittet D:
Effect of screening for methicillin-resistant Staphylococcus aureus
carriage by polymerase chain reaction on the duration of unnecessary
preemptive contact isolation. Infect Control Hosp Epidemiol 2008,
29:1077-1079.
18. Clancy M, Graepler A, Wilson M, Douglas I, Johnson J, Price CS: Active
screening in high-risk units is an effective and cost-avoidant method to
reduce the rate of methicillin-resistant Staphylococcus aureus infection
in the hospital. Infect Control Hosp Epidemiol 2006, 27:1009-1017.
19. Chaberny IF, Schwab F, Ziesing S, Suerbaum S, Gastmeier P: Impact of
routine surgical ward and intensive care unit admission surveillance
cultures on hospital-wide nosocomial methicillin-resistant
Staphylococcus aureus infections in a university hospital: an interrupted
time-series analysis. J Antimicrob Chemother 2008, 62:1422-1429.
20. Huang SS, Yokoe DS, Hinrichsen VL, Spurchise LS, Datta R, Miroshnik I,
Platt R: Impact of routine intensive care unit surveillance cultures and
resultant barrier precautions on hospital-wide methicillin-resistant
Staphylococcus aureus bacteremia. Clin Infect Dis 2006, 43:971-978.
21. Wassenberg MW, Kluytmans JA, Bosboom RW, Buiting AG, van Elzakker EP,
Melchers WJ, Thijsen SF, Troelstra A, Vandenbroucke-Grauls CM, Visser CE,
Voss A, Wolffs PF, Wulf MW, van Zwet AA, de Wit GA, Bonten MJ: Rapid
diagnostic testing of methicillin-resistant Staphylococcus aureus carriage
at different anatomical sites: costs and benefits of less extensive
screening regimens. Clin Microbiol Infect 2011, 17:1704-10.
doi:10.1186/cc11184
Cite this article as: Wassenberg et al.: Costs and benefits of rapid
screening of methicillin-resistant Staphylococcus aureus carriage in
intensive care units: a prospective multicenter study. Critical Care 2012
16:R22.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Wassenberg et al. Critical Care 2012, 16:R22
http://ccforum.com/content/16/1/R22
Page 8 of 8
